Xinnate https://validator.w3.org/feed/docs/rss2.html Xinnate presents TCP-25 data at international dermatology congress Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa Approved clinical trial application for First in Human study on BioC gel Xinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis Bullosa Xinnate receives Orphan Drug Designation from US FDA for TCP-25 Approved clinical trial application for BioC gel on complex wounds Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm Opportunity About Team Xinnate announces successful FDA meeting for TCP-25 Modes of action Scientific Foundation Contact News Xinnate completes Phase 1a/b study with TCP-25 Publications Upcoming events The Unique Concept The Need Test news item Home 2 New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD Excellent results from phase I study shows that the BioC gel is safe and well tolerated. Funding secured for the next step of BioC clinical plan The Market The Competition Idea Concept Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa Xinnate appoints Anna-Karin Lindqvist as new COO Test News 2 Pre-clinical results Test News 3 Xinnate is awarded a prestigious grant from the US Department of Defense Strategy New publication: BioC-coated dressing shows promising effect on both infection and inflammation Funding secured for the first clinical study of BioC wound gel Xinnate has received a prestigious Swedish Research Council grant Great interest for the STM article and coverage in Nature Reviews Drug Discovery Knowledge Platform Breakthrough results published in Science Translational Medicine Xinnate is looking for a Chief Operating Officer Integritetspolicy A new article about BioC results from Lund University IPR Exempelsida Home4